Drug Profile
Research programme: glucose transporter inhibitors - Kadmon
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Kadmon Corporation
- Class Small molecules
- Mechanism of Action Facilitative glucose transport protein inhibitors; Glucose transporter type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 Jul 2021 No recent reports of development identified for preclinical development in Inflammation in USA
- 01 Jun 2017 Preclinical trials in Autoimmune disorders in USA (unspecified route)